Autoimmune Hepatitis Product Line, Clinical Trial Studies, Emerging Drugs, M&A, Licensing, Agreements & Collaborations, and Latest News in 2023 (Updated) – November 9, 2023, 5:08 AM ET

DelveInsight’s Autoimmune Hepatitis Pipeline Insights 2023 report provides comprehensive insights into more than 10 companies and 10 pipeline drugs in the autoimmune hepatitis pipeline space. It covers the autoimmune hepatitis pipeline drug overview, including clinical and non-clinical stage products. It also covers autoimmune hepatitis pipeline therapeutic evaluation by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Autoimmune Hepatitis Pipeline Report *DelveInsight’s Autoimmune Hepatitis Pipeline Report depicts a robust space with more than 10 active players working to develop more than 10 pipeline therapies for the treatment of autoimmune hepatitis. *Leading companies engaged in the autoimmune hepatitis market include Novartis, Taiwan Health Pharmaceutical Co., Ltd.

, Kozar Life Sciences, Jiangsu Hengrui Pharmaceutical Co., Ltd., rejuvenation therapy, Modena Corporation, Parvus Therapeutics, West Geelong Therapeutics, Orbuson Therapeutics, Inc., etc. *Promising autoimmune hepatitis pipeline therapies in various stages of development include Zetomipzomib, HR19042 capsules, JKB-122, budesonide, prednisone, VAY736, and others. *November 2023: Kozar Life Sciences Announced a Phase 2 clinical trial study of Zetomipzomib. This is a Phase 2a, multicenter, placebo-controlled study in which patients with autoimmune hepatitis will receive zetomizomib or placebo in addition to standard treatment for 24 weeks; an optional open-label extension allows patients to receive Zetomizomib (KZR-616) additional 24 weeks of treatment. *October 2023: Novartis Pharmaceuticals Announced Phase 2 and 3 clinical trials of VAY736. This is a randomized, placebo-controlled, double-blind dose-ranging study in autoimmune hepatitis. The study population included female and male adult patients with autoimmune hepatitis who had an incomplete response to or intolerance to standard of care treatment. The diagnosis of autoimmune hepatitis must meet the IAIHG criteria and must be confirmed by liver histology. *August 2023: Jiangsu Hengrui Pharmaceutical Co., Ltd. Announced Phase 2 clinical trial study of HR19042 capsules. This study will evaluate the effectiveness and safety of HR19042 capsules in the treatment of autoimmune hepatitis. It will also explore optimal dosing frequency and dosage for HR19042 capsule therapy.

Request samples and learn about the latest advances in autoimmune hepatitis treatments @Autoimmune Hepatitis Pipeline Reports

In the Autoimmune Hepatitis Pipeline Report, the drug is described in detail, including the drug’s mechanism of action, clinical studies, NDA approvals (if any), and product development activities including technology, autoimmune hepatitis collaborations, licensing, mergers and acquisitions, Funding, name and other product related details.

Autoimmune Hepatitis Overview

Autoimmune hepatitis refers to chronic, progressive inflammation of the liver of unknown origin. The proposed mechanism for the development of autoimmune hepatitis is thought to be the interaction of genetic predisposition, environmental triggers, and malfunction of the innate immune system, leading to chronic inflammation of hepatocytes and subsequent liver fibrosis.

Learn more about Autoimmune Hepatitis Therapeutics Evaluation@Autoimmune Hepatitis Preclinical and Discovery Phase Products

Overview of Emerging Drugs for Autoimmune Hepatitis*Ianalumab: Novartis *JKB-122： Taiwan Medicine

Autoimmune Hepatitis Pipeline Treatment Evaluation

There are approx. More than 10 key companies developing treatments for autoimmune hepatitis. Autoimmune hepatitis companies with most advanced (i.e. Phase II/III) autoimmune hepatitis drug candidates include: Novartis

.

DelveInsight’s Autoimmune Hepatitis Pipeline Report covers about 10+ products in various stages of clinical development such as *Late-stage products (Phase III) *Mid-stage products (Phase II) *Early-stage products (Phase I) and *Pre details -Clinical and discovery stage candidates *Discontinued and inactive candidates

The Autoimmune Hepatitis Pipeline Report provides therapeutic evaluation of pipeline drugs by route of administration. Products have been classified according to different ROA such as *Oral* Parental* Intravenous* Subcutaneous* Topical.

Autoimmune hepatitis pipeline products have been divided into multiple molecular types such as *monoclonal antibodies *peptides *polymers *small molecules *gene therapies

Learn more about the emerging pipeline of therapies for autoimmune hepatitis @Autoimmune Hepatitis Clinical Trial Evaluation

Scope of the Autoimmune Hepatitis Pipeline Report*Coverage – Global*Autoimmune Hepatitis Therapeutic Evaluation by Product Type: Single Agent, Combination, Single Agent/Combination*Autoimmune Hepatitis Therapeutic Evaluation by Clinical Stage: Discovery, Preclinical, Phase I, Phase II, Phase III* Autoimmune Hepatitis Company – Novartis, Taiwan Health Pharmaceutical Co., Ltd., Kozar Life Sciences, Jiangsu Hengrui Pharmaceutical Co., Ltd., rejuvenation therapy, Modena Corporation, Parvus Therapeutics, West Geelong Therapeutics, Orbuson Therapeutics, Inc., etc. *Pipeline therapy for autoimmune hepatitis – Zetomizomib, HR19042 capsules, JKB-122, budesonide, prednisone, VAY736, etc.

For rich insights into new drugs to treat autoimmune hepatitis, visit @Autoimmune Hepatitis Market Drivers and Barriers and Future Outlook

Table of Contents * Introduction * Executive Summary * Autoimmune Hepatitis: Overview * Pipeline Therapeutics * Therapeutic Evaluation * Late-stage Products (Phase III) * Drug Name: Company Name * Drug Profile in Detailed Report….. * Mid-stage Products (II/ Phase III) *Ianalumab: Novartis *Drug profile in detailed report… *Interim product (Phase 2)*JKB-122: Taiwan Health Pharmaceutical Co., Ltd. *Drug profile in detailed report… *Preclinical stage product*mRNA-6981: modern

*Drug Profile in Detailed Report… *Inactive Products*Autoimmune Hepatitis Key Companies*Autoimmune Hepatitis Key Products*Autoimmune Hepatitis-Unmet Need*Autoimmune Hepatitis-Market Drivers and Barriers* Autoimmune Hepatitis – Future Outlook and Conclusions *Autoimmune Hepatitis Analyst View *Autoimmune Hepatitis Key Companies *Appendix

For more information on the autoimmune hepatitis pipeline therapeutics, please contact Autoimmune Hepatitis Unmet Needs and Analyst Views

about Us

DelveInsight is a leading healthcare-focused market research and consulting firm, providing clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we provide customized research solutions and insights to clients around the world. Contact us for high-quality, accurate and real-time intelligence to stay ahead of the growth curve.

Media Contact

company Yam: DelveInsight Business Research LLP

contact person: Yash Bhardwaj

Email: ybhardwaj@delveinsight.com

Tel: 9193216187

address:304 S. Jones Avenue Chapter 2432

City: las vegas

State: Nevada

nation: USA

website: https://www.delveinsight.com/report-store/autoimmune-hepatitis-market

Source: www.abnewswire.com

.